About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5775427
Allelic
Composition
Cox10tm1Ctm/Cox10tm1Ctm
Slc6a3tm1.1(cre)Bkmn/?
Genetic
Background
B6.Cg-Cox10tm1Ctm Slc6a3tm1.1(cre)Bkmn
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cox10tm1Ctm mutation (1 available); any Cox10 mutation (4 available)
Slc6a3tm1.1(cre)Bkmn mutation (1 available); any Slc6a3 mutation (50 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• mice exhibit a decline in motor activity and coordination by 2 months of age, maximum decline is reached by 4 months of age
• mice are not able to perform the pole test by 2 months of age, however, treatment with high dose L-DOPA (25 mg/kg) or pioglitazone improves performance
• impaired rotarod performance by 2 months of age, however, treatment with high dose L-DOPA (25 mg/kg) or pioglitazone improves performance
• walking time is decreased on rotarod at 4 and 6 months as compared to younger animals
• decrease in rearing activity by 2 months of age, maximum decline is reached by 4 months of age
• mice move less during nocturnal cycle and in open field test (distance travelled) as compared to controls; treatment with high dose L-DOPA (25 mg/kg) results in hyperactivity and stereotypic movements
• maximum decline in motor performance is reached at 4 months of age

hematopoietic system
• activation of microglial cells in midbrain as detected by Iba1 immunoreactivity
• treatment with pioglitazone for 4 months results in reduction in Iba1 immunoreactivity in midbrain

growth/size/body
• pups are born at a lower body weight than controls and remain at a lower weight throughout life
• administration of pioglitazone increases weight to control levels

immune system
• activation of microglial cells in midbrain as detected by Iba1 immunoreactivity
• treatment with pioglitazone for 4 months results in reduction in Iba1 immunoreactivity in midbrain
• CXCL10 and CCL2 are increased in striatum
• in midbrain, levels of IL6, IL10, CXCL10 and CCL2 trend upward, but do not reach significance
• increase in IL1B in midbrain in 2 month old mice
• IL1B is slightly increased in striatum but does not reach significance

homeostasis/metabolism
• decrease in dopamine and dopamine metabolites (to a lesser extent) in striatum by 2 months of age as compared to controls
• dopamine depletion continues through out life but does not worsen

nervous system
• activation of microglial cells in midbrain as detected by Iba1 immunoreactivity
• treatment with pioglitazone for 4 months results in reduction in Iba1 immunoreactivity in midbrain
• substantial loss of dopaminergic cell bodies in the substantial nigra as measured by reduction of tyrosine hydroxylase (TH) and dopamine transporter (DAT) content
• widespread axonal degeneration in striatum

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Parkinson's disease DOID:14330 OMIM:607688
OMIM:610297
OMIM:613643
OMIM:614251
OMIM:PS168600
J:231810


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/12/2019
MGI 6.14
The Jackson Laboratory